Latest Intelligence in the Pharmaceutical and Healthcare Industry (September 4–7, 2026)

On September 3, CanSino Biologics announced that its PD-1/VEGF bispecific antibody, Ivolucimab, met the key secondary endpoint of overall survival (OS) in the Phase III HARMONi-2 trial—comparing monotherapy with pembrolizumab (Keytruda) as first-line treatment for PD-L1-positive non-small cell lung cancer (NSCLC). The result was statistically significant and clinically meaningful. Earlier, in May 2024, the trial had already met its primary progression-free survival (PFS) endpoint (median PFS: 11.14 vs. 5.82 months; HR = 0.51). This OS success makes Ivolucimab the first chemotherapy-free regimen achieving dual positive outcomes for both PFS and OS. On September 4, the company’s stock surged 11.45% in a single day. With this head-to-head victory over Keytruda—including robust OS validation—the domestic bispecific antibody has transitioned from 'impressive efficacy' to 'confirmed overall survival benefit,' strengthening China’s bargaining position in global pricing negotiations. www1.hkexnews.hk/listed... ▸ China Biopharmaceuticals’ Bispecific ADC TQB2102 Meets Phase III Endpoint and Is Licensed to Cipla Zhengda Tianqing (a subsidiary of China Biopharmaceuticals) announced that its self-developed HER2-targeting bispecific antibody–drug conjugate (ADC), injectable TQB2102, met the pre-specified primary endpoint in its Phase III trial for HER2-low recurrent/metastatic breast cancer. The company claims it is the world’s first innovative drug of its kind to successfully complete Phase III development. The Center for Drug Evaluation (CDE) has issued written approval for an imminent new drug application (NDA). On August 31, Zhengda Tianqing entered into an exclusive licensing and supply agreement with India’s Cipla, granting rights to TQB2102 in seven emerging markets—including India and South Africa—with potential total payments reaching up to USD 123 million (including double-digit sales royalties). TQB2102’s Phase III success coincided with immediate licensing to emerging markets—demonstrating synchronized clinical advancement and commercialization. Domestic ADC developers are accelerating global expansion through a dual strategy of ‘clinical efficacy + strategic licensing.’ finance.sina.com.cn/rol... V. Scientific and Academic Frontiers ▸ China’s First AI-Assisted, De Novo Drug “Aipuswei” Granted Conditional Approval by NMPA Yisitevi Hydrochloride Tablets (brand name: Aipuswei), a Class 1 novel drug jointly developed by Westlake University, Westlake Laboratory, and Westlake Pharmaceuticals, received conditional marketing approval from China’s National Medical Products Administration (NMPA) for treating mild-to-moderate COVID-19 in adults. It is China’s first de novo drug approved based on AI-assisted discovery—and the world’s first small-molecule novel drug approved globally leveraging DNA-encoded library (DEL) technology. From target identification to clinical completion, the entire process took only three and a half years, marking AI’s proven capacity to support end-to-end novel drug development and regulatory approval. China’s first AI-assisted de novo drug receiving conditional approval signals the transition of AI-driven drug discovery from technical validation to real-world implementation—and sets a regulatory benchmark for cost reduction and acceleration in pharmaceutical R&D. finance.sina.com.cn/wm/... ▸ Nature Medicine: China’s “Mother-Child AI Agents” Predict Maternal and Neonatal Risks Ahead of Time Chinese researchers published a study in Nature Medicine describing MoChiAgent—a clinical decision-support tool powered by large language models (LLMs)—with its core engine named MoChiFormer. By integrating longitudinal electronic health records and routine laboratory test data, MoChiAgent enables temporal risk prediction for maternal and neonatal outcomes.

West Lake Electronics Plans to Reduce Its Stake in Huashu Media: Strategic Adjustment or Funding Need?

This marks the first time West Lake Electronics Group has reduced its stake in Huashu Media since its initial investment. Dong Lin, Researcher at Investment Times Network & Biaodian Finance Will the shareholder structure of Huashu Media Holding Co., Ltd. (hereinafter “Huashu Media,” stock code: 000156.SZ) undergo another shift? Recently, Huashu Media announced that West Lake Electronics Group Co., Ltd. (“West Lake Electronics Group”), a shareholder holding more than 5% of the company’s shares, plans to reduce its holdings via centralized bidding between January 14 and April 13, 2026—selling no more than 18.5293 million shares, representing up to 1% of the company’s current total share capital. According to the announcement, this reduction stems from West Lake Electronics Group’s comprehensive considerations regarding its own strategic development, operational needs, and key project investments. As per the latest financial report, as of the end of Q3 2025, Huashu Media’s top three shareholders were: Huashu Digital TV Media Group (holding 36.43%); Zhejiang Yitong Media and West Lake Electronics Group—tied as the second-largest shareholders, each holding 7.74%. Investment Times Network and Biaodian Finance researchers noted that this is West Lake Electronics Group’s first share reduction since its initial investment. Notably, Zhejiang Yitong Media previously disclosed a share reduction plan—to sell up to 18.5293 million shares (also up to 1% of total share capital) between September 9 and December 8, 2025. However, during the execution period, Yitong Media did not carry out any reduction, leaving its shareholding quantity and proportion unchanged. From the perspective of secondary-market shareholder numbers, as of the end of Q3 2025, Huashu Media had a total of 42,700 registered shareholders—a 9.37% decline from the end of the previous half-year. Meanwhile, average per-account market value rose to RMB 348,500, indicating increased shareholding concentration. Huashu Media Announces Pre-Disclosure of Share Reduction by Shareholder Holding More Than 5% Source: Company Announcement As a representative enterprise in the television broadcasting sector, Huashu Media’s core businesses include cable TV network services, nationwide new media operations, broadband network services, and smart city solutions. In the first half of 2025, group customer integration projects accounted for 30.25% of revenue; internet TV business contributed 19.46%; broadband and data communications accounted for 15.57%; and digital TV services represented 11.61%. Impacted by declining performance across core business segments, Huashu Media’s net profit attributable to shareholders of the parent company stood at RMB 793 million in 2022, RMB 689 million in 2023, and RMB 534 million in 2024—reflecting year-on-year growth rates of −12.59%, −13.07%, and −22.50%, respectively, showing a continuous downward trend. Breaking down by business segment, in 2024, only the technology division’s smart city digitalization business recorded revenue growth; meanwhile, interactive TV business revenue fell by 20.67%; national new media business revenue declined 11.04% year-on-year; and smart home business revenue dropped 3.82% year-on-year. Regarding the performance decline, Huashu Media explained in its annual report that rapid development of the internet audiovisual industry has intensified audience fragmentation and competition, thereby eroding profitability in certain traditional business lines.

Westlake Announces Third Quarter 2026 Conference Call

Oct 21, 2026

Westlake Chemical Corporation will release its third-quarter 2026 earnings on November 4, 2026, before market open, followed by a conference call at 11:00 a.m. ET.

GlobeNewswire

Westlake Corporation to Report Third Quarter 2026 Earnings on November 4 and Host Conference Call

Quiver Quantitative

Westlake Chemical Partners Announces Third Quarter 2026 Conference Call

The Manila Times

2026-01-04

Expectations for Global PVC Production Cuts Intensify

2026-02-24

Westlake Q4 Earnings Beat Amid Accelerated Cost Cutting

2026-03-02

Westlake Chemical Partners LP Filed Annual Report